If you're looking for some shares to buy in November, then you might want to take a look at the three buy-rated shares listed below.
Here's why they are highly rated:
Altium Limited (ASX: ALU)
Altium is the electronic design software platform provider responsible for the award-winning Altium Designer product. Demand for its platform has been growing strongly in recent years thanks to its exposure to the rapidly growing Internet of Things and artificial intelligence (AI) markets. Management expects this to continue and is aiming to increase its revenue by 150% to US$500 million by 2025-26.
One broker that is positive on its chances of achieving this is Morgan Stanley. Its analysts have an overweight rating and $40.00 price target on the company's shares.
Appen Ltd (ASX: APX)
Appen is a leading developer of high-quality, human annotated datasets for machine learning and AI. It prepares and/or creates the data for the machine learning models of some of the largest tech companies such as Facebook and Microsoft. This is a vital part of the development process, as without high quality data a model will never reach its potential.
Analysts at Macquarie believe Appen is well-placed for growth over the medium term thanks to AI tailwinds. The broker has an outperform rating and $43.00 price target on the company's shares.
CSL Limited (ASX: CSL)
CSL is one of the world's leading biotherapeutics companies. It is comprised of the CSL Behring business and the Seqirus influenza vaccine business. Both businesses have been growing their top lines at a solid rate in recent years. This has been driven by increasing demand for immunoglobulins, its growing plasma collection network, and its high level of investment into research and development.
One broker that is confident that there will be more of the same in the future is UBS. Its analysts recently slapped a buy rating and $346.00 price target on the company's shares.
